Viral vectors—beyond the yellow brick road

Home » Insights » Viral vectors—beyond the yellow brick road

Peter Walters

Fellow - Advanced Therapies

Jan Bondoc, AIA

Process Architect

The science of viral vector manufacturing is generating a lot of excitement, and companies in this space are under pressure to move fast and make cost-effective decisions; this can occasionally result in speed at the expense of due diligence.

A facility must be more than capable of manufacturing viral vectors at a commercial scale. It should be designed to operate smoothly, cost-effectively, and with maximum efficiency. This requires a close examination of assumptions and decisions.

As the industry gallops forward, some will succeed in the lab but struggle to scale. Others will design sophisticated processes that accomplish what no facility has accomplished before but at such a high cost per square foot that they’ll struggle to reach profitability. The real test will come in five years when we survey those who are left standing. What choices are those “survivors” making right now, in their early stages of growth, to de-risk their future production?

“We have seen the growth of cell and gene therapy and along with it is the increase in demand for viral vectors. ”

To answer that question, this webinar explores:

The viral vector industry
The science of viral vectors
The manufacturing process
The optimal facility design for different viral vector types
The future of the technology

Listen to the webinar to understand the interdependent factors that contribute to an efficient and reliable throughput of viral vector products at a commercial scale.